To observe the clinical efficacy and safety of bevacizumab injection combined with paclitaxel injection and carboplatin injection in the treatment of patients with advanced ovarian cancer.

Patients with advanced ovarian cancer were randomly divided into control group and treatment group. The control group was given 175 mg·m^-2 paclitaxel once every 3 weeks, the intravenous infusion was not less than 3 h + 0.3 - 0.4 g·m^-2 carboplatin once every 3 weeks, intravenous infusion. On the basis of control group, the treatment group was given 15 mg·kg^-1 bevacizumab once every 3 weeks, intravenous infusion. Two groups were treated for 6 courses with 3 weeks per course. The clinical efficacy, tumor markers, vascular related factors, T lymphocyte and miRNA-30 levels, survival during treatment and safety were compared between two groups.

Treatment group was enrolled 71 cases, 10 cases dropped out, and 61 cases were finally included in the statistical analysis. Control group was enrolled 70 cases, 10 cases dropped out, and 60 cases were finally included in the statistical analysis. After treatment, the disease remission rates of treatment and control groups were 60.66% (37 cases/61 cases) and 41.67% (25 cases/60 cases) with statistically significant difference (P<0.05). After treatment, the cluster of differentiation 133 levels were (11.44±2.46) and (26.77±5.41) U·mL^-1, the DEAD-box helicase 4 levels were (13.55±3.48) and (33.16±5.46) U·mL^-1, the relative expression levels of miRNA-30b were 1.03±0.07 and 1.15±0.08, the relative expression levels of miRNA-30c were 1.09±0.05 and 1.22±0.06, the differences were statistically significant (all P<0.05). During follow-up, all-cause deaths of treatment and control groups were 8 and 11 cases, the survival rates were 86.89% and 81.67% (all P>0.05). The adverse drug reactions in both groups were mainly gastrointestinal reactions, alopecia, allergies and liver dysfunction. The total incidences of adverse drug reactions in the treatment and control groups were 55.74% and 43.33%, without significant difference (P>0.05).

Bevacizumab injection combined with paclitaxel injection and carboplatin injection has better clinical efficacy in the treatment of patients with advanced ovarian cancer than paclitaxel injection combined with carboplatin injection, the former can significantly reduce the levels of tumor markers, improve immune function, without increasing the incidence of adverse drug reactions.